The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations
Abstract
You have accessJournal of UrologyCLINICAL UROLOGY: Special Communications1 Aug 2003AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendationsis corrected byERRATA AUA PRACTICE GUIDELINES COMMITTEE AUA PRACTICE GUIDELINES COMMITTEE View All Author Informationhttps://doi.org/10.1097/01.ju.0000078083.38675.79AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail Benign prostatic hyperplasia (BPH), one of the most common diseases of aging men, 1 can be associated with bothersome lower urinary tract symptoms (LUTS) that affect quality of life by interfering with normal daily activities and sleep patterns. The prevalence of histopathologic BPH is age dependent, with initial development usually after 40 years of age. 2 By 60 years of age, its prevalence is greater than 50% and by age 85 it is as high as 90%. Similar to that of histologic evidence, the prevalence of bothersome symptoms also increases with age. Approximately half of all men who have a histologic diagnosis have moderate to severe LUTS. 1 Because long-term data from population-based studies have only recently become available, the risks of developing complications and morbidities from untreated BPH are unclear. For example, despite recent evidence, there is still uncertainty regarding the likelihood that a patient with a specific symptom complex will develop complete urinary retention within a particular time frame. Nonetheless, BPH associated mortality is rare in the United States, and serious complications are uncommon. In contrast, LUTS are bothersome to many patients, and the amount of bother may differ greatly among individuals with the same degree of symptom frequency and severity. 3 Since the impact of LUTS on the patient's quality of life is highly variable and not directly related to any measurable physiological factors, the patient's perception of the severity of the condition, as well as the degree to which it interferes with his lifestyle or causes embarrassment, should be the primary consideration in choosing therapy. 4,5 In the past decade, there have been significant changes in the available treatment options for BPH. New forms of medical and minimally invasive treatments have been approved by the United States Food and Drug Administration (FDA) while other therapies have become obsolete. This update of the 1994 AHCPR benign prostatic hyperplasia clinical practice guideline produced by the Agency for Health Care Policy and Research of the United States Department of Health and Human Services (AHCPR; now known as the Agency for Healthcare Research and Quality) was developed by a panel of experts (hereafter the Panel) chosen by the American Urological Association (AUA) Practice Guidelines Committee. Using an evidence-based approach, the multidisciplinary Panel focused on providing scientifically based information on currently available BPH treatment modalities. Because the Panel strongly believes that the patient should play a central role in determining his need for treatment, it set out to address the issue of whether or not there was sufficient evidence for outcomes (both benefits and risks) to be estimated. Thus, this guideline is intended to provide scientifically based information on treatment outcomes so that physicians can assist their patients in making appropriate treatment decisions. DEFINITIONS AND TERMINOLOGY Benign prostatic hyperplasia is defined histologically as a disease process characterized by stromal and epithelial cell hyperplasia beginning in the periurethral zone of the prostate. 6,7 The chief complaint of the patient with BPH is usually bothersome LUTS typified by urinary frequency, urgency, nocturia, decreased and intermittent force of stream and the sensation of incomplete bladder emptying. The relationship between BPH and LUTS is complex, however, because not all men with histological evidence of BPH will develop LUTS. In addition, LUTS are neither specific to nor exclusive of BPH; other conditions in the lower urinary tract and elsewhere may be causative. Moreover, not all patients with BPH and LUTS will have prostate enlargement, and prostate enlargement may exist in the absence of LUTS. The 4th International Consultation on BPH recommended the use of the general terminology LUTS or "LUTS suggestive of BPH" in place of the older term "prostatism" until a cause-and-effect BPH-symptom relationship has been established. 8 Recognizing the complexities of this nomenclature, the Panel decided that the term "BPH" would be used in this document when referring to any symptomatic conditions characterized by bothersome LUTS attributed to histological hyperplasia or increased tone of the prostate. METHODOLOGY As in the development of the 1994 AHCPR guideline, a systematic literature review was conducted based on the results of a MEDLINE® search. The search, which spanned the years from 1991 through e
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia
Barry, M. J., Fowler, F. J., O’Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., Cockett, A. T. K., & The Measurement Committee of the American Urological Association (1992) · Journal of Urology · doi:10.1016/s0022-5347(17)36966-5 · Cited by 3,436
The Development of Human Benign Prostatic Hyperplasia with Age
Berry, S. J., Coffey, D. S., Walsh, P. C., & Ewing, L. L. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)49698-4 · Cited by 2,488
Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer
Catalona, W. J., Smith, D. S., Ratliff, T. L., Dodds, K. M., Coplen, D. E., Yuan, J. J. J., Petros, J. A., & Andriole, G. L. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241702 · Cited by 2,361
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.15.1967 · Cited by 1,499
The Effect of Finasteride in Men with Benign Prostatic Hyperplasia
Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210223271701 · Cited by 1,124
The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia
Lepor, H., Williford, W. O., Barry, M. J., Brawer, M. K., Dixon, C. M., Gormley, G., Haakenson, C., Machi, M., Narayan, P., & Padley, R. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350801 · Cited by 792
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Wasson, J. H., Reda, D. J., Bruskewitz, R. C., Elinson, J., Keller, A. M., & Henderson, W. G. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501123320202 · Cited by 605
PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING
POLASCIK, T. J., OESTERLING, J. E., & PARTIN, A. W. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68543-6 · Cited by 599
Cited by
Madersbacher, S., Alivizatos, G., Nordling, J., Sanz, C. R., Emberton, M., & de la Rosette, J. J. M. C. H. (2004) · European Urology · doi:10.1016/j.eururo.2004.07.016 · Cited by 622
Gacci, M., Eardley, I., Giuliano, F., Hatzichristou, D., Kaplan, S. A., Maggi, M., McVary, K. T., Mirone, V., Porst, H., & Roehrborn, C. G. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.037 · Cited by 279
5α-Reductases in human physiology: an unfolding story
Traish, A. M. (2012) · Endocrine Practice · doi:10.4158/ep12108.ra · Cited by 57
Metadata
- Authors
- AUA PRACTICE GUIDELINES COMMITTEE
- Venue
- Journal of Urology
- Published
- 2003-08
- Volume
- 170
- Issue
- 2
- Pages
- 530-547
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W4236163484
- Cited by
- 844
- References
- 34
- FWCI
- 65.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations. https://app.cochat.ai/papers/10.1097/01.ju.0000078083.38675.79
- The paper
- AUA PRACTICE GUIDELINES COMMITTEE. (2003). AUA Guideline on Management of Benign Prostatic Hyperplasia (2003). Chapter 1: Diagnosis and Treatment Recommendations. Journal of Urology. https://doi.org/10.1097/01.ju.0000078083.38675.79
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.